October 2005
« September 2005 | Main | November 2005 »
October 21, 2005
New Diabetes Pill Deemed Dangerous
Peroxisome proliferator–activated receptors (PPARs) are nuclear transcription factors that modulate gene expression. Therapeutic agents targeting 2 distinct families of PPARs ( and ) have been introduced in the United States. The first dual-PPAR agonist, muraglitazar, was reviewed by a US Food and Drug Administration (FDA) advisory committee on September 9, 2005, resulting in a vote of 8:1 recommending approval for its use in controlling blood glucose levels in patients with type 2 diabetes.
... moreOctober 18, 2005
First Degree Murder Alleged
This just makes me sick: Jury selection took place Monday in the case of Cheryl Musso, formerly known as Botzet. Musso is charged with first degree murder in the death of her 11 year old daughter Ariel. Ariel was a... ... moreStudies Support Intensive Therapy
Two decent studies were reported in the Annals of Internal Medicine that concluded treatment with inhaled insulin or exenatide, an injectable drug, can improve diabetes management in individuals with Type 2 diabetes. In one study, Dr. Julio Rosenstock, from the... ... morePosted at 12:59 PM | TrackBack
Stem Cell Treatment for Peripheral Vascular Disease
Revascularization is one of the things that stem cell therapy can do to damaged areas of the heart. But what about other areas of the body? People suffering from Peripheral Vascular Disease (PVD) are at risk of losing limbs due... ... moreOctober 15, 2005
Text Messaging Diabetes
Mobile text messaging by families throughout the US has been used to close the gap when their kids with diabetes are at school or anytime they are away from home ... more here.... ... moreStem Cell Research and Diabetes
The Plureon Corporation has entered into an agreement with BD (Becton, Dickinson and Company) in the field of diabetes research and development using Plureon's platform stem cell technology. This is great news for individuals with diabetes because it puts the... ... morePosted at 12:17 PM | TrackBack